Open an account

Zymeworks

ZYME · NASDAQ

$26.91+$1.37 (+5.36%)TodayMarket closed ·
Prev close $25.54

About ZYME

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company is headquartered in Middletown, Delaware and currently employs 264 full-time employees. The company went IPO on 2019-06-24. The firm is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.

Employees
264
Headquarters
Middletown, Delaware
Listed
Jun 24, 2019
Sector
Health Care
Industry
Biotechnology
Website
zymeworks.com

ZYME key statistics

Market cap
1.63B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.15M
Volume
3.13M
Open price
$25.76
High today
$27.20
Low today
$25.71
52 Week high
$31.34
52 Week low
$16.00

Zymeworks (ZYME) at a glance

Zymeworks (ZYME) last traded at $26.91, with a market cap of 1.63B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $25.71 and $27.20. The current price is 4.7% above the day's low and 1.1% below its high.

Volume so far is 3.13M shares, above the average of 1.15M shares a day.

Over the past year Zymeworks has ranged from $16.00 to $31.34, and now sits 71% of the way up that range.

Zymeworks met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.62 per share against an estimate of -$0.4955.

The average analyst price target is $42.33, 57.3% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 12 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 15 analystsAvg $42.33
Low
$32.32
Now
$26.91
High
$63.00

ZYME earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 39.5% on average.

  1. Q3 FY24: reported -$0.39 per share against an estimate of -$0.4035
  2. Q4 FY24: reported -$0.31 per share against an estimate of -$0.101
  3. Q1 FY25: reported -$0.30 per share against an estimate of -$0.4167
  4. Q2 FY25: reported $0.03 per share against an estimate of -$0.5042
  5. Q3 FY25: reported -$0.26 per share against an estimate of -$0.3276
  6. Q4 FY25: reported -$0.55 per share against an estimate of -$0.4246
  7. Q1 FY26: reported -$0.59 per share against an estimate of -$0.1958
  8. Q2 FY26: reported -$0.62 per share against an estimate of -$0.4955

ZYME news

  • Vandana Singh

    Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal

  • Vandana Singh

    Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

  • Press releasePRNewswire

    A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

  • Vandana Singh

    Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition

  • Zymeworks Said To Near $929M Deal For Theravance At $17 Per Share, Bloomberg News Reports

  • Press releasePRNewswire

    Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery

  • Forecasting The Future: 4 Analyst Projections For Zymeworks

  • Press releaseGlobe Newswire

    Zymeworks Outlines Strategic Priorities and Outlook for 2026

Similar companies

Companies in the same industry as Zymeworks

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.